BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

CONCLUSIONS: We provide evidence that BETi either alone or in combination with FGFR1 inhibitors or BH3 mimetics may be a useful therapeutic strategy for recurrent ILC patients. PMID: 31409615 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Related Links:

CONCLUSIONS: We provide evidence that loss of E-cadherin hyperactivates the IGF1R pathway and increases sensitivity to IGF1R/InsR targeted therapy, thus identifying the IGF1R pathway as a potential novel target in E-cadherin deficient breast cancers. PMID: 29941485 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
The objective of the current study was to compare the relative impact of adjuvant chemotherapy on the survival of patients with ILC versus those with IDC. METHODSWomen with estrogen receptor (ER)‐positive, human epidermal growth factor receptor 1 (HER2) ‐negative, stage I/II IDC and ILC who received endocrine therapy were identified from the 2000 to 2014 California Cancer Registry. Patient, tumor, and treatment characteristics were collected. Ten‐year overall survival (OS) was estimated using the Kaplan‐Meier method and Cox proportional‐hazards modeling. RESULTSIn total, 32,997 women with IDC and 4638 with ILC we...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Abstract The great majority of invasive lobular carcinoma (ILC) is estrogen-dependent luminal A type carcinoma but the details of estrogen actions and its intratumoral metabolism have not been well studied compared to invasive ductal carcinoma (IDC). We first immunolocalized estrogen-related enzymes including estrogen sulfotransferase (EST), estrogen sulfatase (STS), 17β-hydroxysteroid dehydrogenase (HSD) 1/2, and aromatase. We then evaluated the tissue concentrations of estrogens in ILC and IDC and subsequently estrogen-responsive gene profiles in these tumors in order to explore the possible differences and...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer, affecting ~30,000 U.S. women annually. Over 90% of ILC are estrogen receptor (ER)-positive, however, endocrine therapy may have poorer efficacy in a subset of ILC patients compared to invasive ductal carcinoma (IDC) patients. Based on these observations, we assessed genome-wide ER-mediated gene expression and ER genomic binding in ILC cell lines MDA MB 134VI (MM134) and SUM44PE (44PE), to identify novel mediators of ER signaling and putative therapeutic targets specifically in ILC.Among ILC-specific estrogen-regulated genes, the most strongly indu...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Luminal Breast Cancer: Poster Presentations - Proffered Abstracts Source Type: research
Conclusions:FO utilization is variable based on MBC sub-type and the timing of tissue collection is bimodal. ESR1 mutations were associated with history of prolonged endocrine rx treatment in ER+ IDC and CDH1 mutations were associated with ILC. FO assays frequently influenced clinical treatment decisions but did not result in a high number of pts enrolled on clinical trials. We will update our dataset with additional FO assays and clinicopathologic variables.Citation Format: Harnden KK, Kimmick GG, Marcom PK, Westbrook KE, Blackwell KL. The foundation one assay influences clinical decision making in metastatic breast cance...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
It has been recognized for many years that there exist pathological entities associated with an increased risk of invasive breast cancer. The most frequently encountered are atypical hyperplasia (AH), lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS), although other diagnoses have also been identified. Often these lesions are discovered incidentally, and when diagnosed are found to confer a wide range of elevated breast cancer risk. Clinical management of these conditions has largely consisted of surveillance, sometimes with the addition of endocrine therapy.The selective estrogen receptor modulators (SE...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Invited Speaker Abstracts Source Type: research
IntroductionBreast cancer is a heterogeneous disease with distinct biological subtypes. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the two most frequent histological breast cancer subtypes. With this study, we aimed to provide insight into the role of histological subtype on the characteristics, choices with respect to systemic therapy in daily practice and outcome of patients with metastatic breast cancer.Patients and methodsWe analyzed 815 patients diagnosed with metastatic breast cancer in eight hospitals between 2007 and 2009. All hormone receptor (HR) positive patients with either IDC or ...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Invasive lobular carcinoma (ILC) is the eighth most frequently diagnosed cancer in any organ, and accounts for 8-11% of breast cancer. This histological subtype is characterized by loss of E-cadherin, and favorable prognostic factors, such as low Ki67 and high rates of ER/PR-positive tumors. Only recently is the lobular subtype gaining recognition as a distinct disease, displaying a unique growth pattern, unique molecular changes in addition to loss of E-cadherin, and evidence for late recurrences and reduced response to targeted endocrine therapy. It is widely accepted that a late age at first full term birth (FFTB) incre...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Discussion Abstracts Source Type: research
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer representing 10-15% of newly diagnosed breast tumors. Over 90% of ILC are estrogen receptor (ER)-positive, however, endocrine response and estrogen signaling are not well understood in ILC. Retrospective analyses suggest that ILC patients treated with endocrine therapy have poorer outcomes than invasive ductal carcinoma (IDC) patients, and that ILC patients may not benefit from adjuvant tamoxifen. Based on these observations, we hypothesize that ER regulates unique signaling pathways in ILC cells that control growth and endocrine response.To identi...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
ConclusionsctDNA is a sensitive test for detection of ESR1 in HR+ MBC patients, with the advantage of being a blood based assay which lends itself to serial analysis. In this patient population ctDNA can be a helpful tool to predict response to ET and predict treatment failure.Citation Format: Austin L, Rodriguez A, Jaslow R, Fortina P, Nagy R, Zill O, Talasaz A, Cristofanilli M. Detection of activating estrogen receptor 1 (ESR1) in circulating tumor DNA (ctDNA) in hormone-receptor positive metastatic breast cancer (MBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium:...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Ductal Carcinoma | Endocrine Therapy | Lobular Carcinoma | Study